Viatris: Mylan, EpiPen Legacy, and Turnaround

Jack traces Viatris's Mylan and Upjohn merger, EpiPen controversy, and modest expected earnings improvement post-merger.

Play episode from 27:40

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!